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Abstract
Background—Coxiella burnetii, an obligate intracellular organism, is the causative agent of the 
zoonotic disease Q fever. The seroprevalence rate for Q fever in the United States is 3.1%, 
suggesting a high number of infections each year. However, less than 200 cases of Q fever are 
reported to the CDC annually. This discrepancy is likely the result of underutilized diagnostics and 
a high percentage (>50%) of asymptomatic infections. The detection of C. burnetii in patient 
blood during the first 2–3 weeks of infection raises the possibility that the organism could be 
present in donated human blood. The purpose of this study was to determine if extracellular C. 
burnetii would be stable in blood under normal storage conditions.
Study Design and Methods—Donated human blood was separated into whole blood, 
leukoreduced whole blood, packed RBCs, and plasma. Each component was spiked with purified, 
extracellular C. burnetii strain Nine Mile Phase 1, and the viability and infectivity of the 
organisms were tested weekly.
Results—C. burnetii did not decrease in viability or the ability to infect cells after storage in any 
of the blood products, even after six weeks of storage at 1–6°C.
Conclusions—Extracellular C. burnetii can survive and remain infectious in donated blood 
products.
Introduction
Coxiella burnetii is a gram-negative bacterium that causes the zoonotic disease Q fever. It is 
considered a category B agent of bioterrorism due to its low infectious dose, transmission by 
inhalation, and environmental stability1. Humans typically acquire Q fever after inhalation 
of contaminated aerosols that are derived from the waste products of infected animals. The 
most common reservoirs related to human infection are sheep and goats2. The presentation 
of Q fever in its acute form can include fever, headache, malaise, and myalgia3. An atypical 
pneumonia is often seen. A small percentage (2–5%) of C. burnetii infections result in a 
chronic disease that is difficult to treat and can present as a life-threatening endocarditis.
Q fever has been a nationally notifiable disease in the US since 1999, with reported cases 
never exceeding 200 in any given year. However, a study conducted using samples from the 
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2003–2004 survey cycle of the National Health and Nutrition Examination Survey found 
that seroprevalence in the United States was 3.1%, suggesting that many cases of Q fever go 
unreported4. Reasons for under-reporting of Q fever probably include the non-specific 
nature of its symptoms, difficulties in diagnosis, and the possibility that more than 50% of 
infections may be asymptomatic in humans3.
During acute Q fever, C. burnetii can be detected by PCR in blood and serum up to 17 days 
after the onset of symptoms5, but the presence of C. burnetii DNA in the blood typically 
declines after the emergence of the antibody response. In patients with chronic Q fever it is 
also possible to detect C. burnetii in blood months after the initial infection6. In a screen of 
blood donors from the Netherlands during a large outbreak of Q fever in 2009, 3/1004 
(0.3%) blood donors tested positive for C. burnetii DNA by PCR and showed an antibody 
response, but none of these donors reported Q fever symptoms7. Thus, it is possible for 
asymptomatic, C. burnetii-infected donors to introduce C. burnetii into the blood supply. 
However, transmission of C. burnetii by transfusion has not been documented.
The length of time that C. burnetii can remain viable and infectious in stored blood is not 
known. C. burnetii has the ability to form a spore-like “small cell variant” (SCV) when it is 
not replicating, and this SCV form of C. burnetii has been reported to be very stable in a 
variety of environments8. However, very little is known about the survival of C. burnetii in 
human blood under normal storage conditions. In this study, human blood and blood 
products were spiked with purified C. burnetii, and the survival of the bacteria under normal 
storage conditions was monitored.
Materials and Methods
Five hundred mls of blood was obtained from each of 3 healthy human donors. Blood was 
drawn into a leukotrap WB system CPDA-1 double blood bag unit (Pall Medical, Covina, 
CA). An aliquot of whole blood was removed from each unit prior to leukoreduction. The 
blood was then leukoreduced using the leukotrap filter of the WB system (Pall Medical, 
Covina, CA). After an aliquot of leukoreduced blood was taken, the leukoreduced blood was 
separated into packed RBCs and plasma according to the manufacturer’s instructions. Blood 
was obtained in accordance with the ethical standards of the institutional review boards of 
Emory University and the Centers for Disease Control and Prevention.
Aliquots (40 mls) of whole blood, leukoreduced whole blood, packed RBCs, and plasma 
were placed in 50 ml conical tubes and spiked with approximately 1.6 × 106 genome 
equivalents of purified C. burnetii strain Nine Mile Phase 1 (RSA493). Aliquots of 600 µl 
were taken from each sample immediately after spiking, and then the tubes were stored at 1–
6°C. At days 7, 14, 22, 28, 35, and 42 the samples were gently mixed and additional 600 µl 
aliquots were taken.
For each time point, 10 µl of the aliquot was plated on a 100 mm plate containing ACCM-2 
in 1% agarose and overlayed with ACCM-2 in 0.25% agarose. ACCM-2 was made 
according to published instructions9. The plates were incubated at 37°C in a tri-gas 
incubator (Thermo Scientific Heracell 150i, Waltham, MA), at 2.5% O2, 5% CO2, and 
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92.5% N2. Colonies were counted 14 days after plating. Also for each time point, 200 µl of 
the aliquot was introduced into a T-25 flask containing a 70% confluent monolayer of rabbit 
kidney (RK-13) cells. At 7 and 14 days after inoculation, 200 µl of the culture media was 
removed, DNA isolated using a QIAmp DNA mini kit tissue protocol (Qiagen, Valencia, 
CA), and quantitative PCR targeting IS1111 was performed as described previously10.
Results
Whole blood from three random donors was separated into leukoreduced blood, RBCs, and 
plasma. Aliquots (40 mls) of each type of blood product were stored at 1–6°C, spiked with 
C. burnetii strain Nine Mile Phase 1, and samples were taken weekly for analysis. Although 
C. burnetii is an obligate intracellular bacterium, recent work has shown that C. burnetii can 
be grown on plates using a unique semisolid agarose medium and a microaerobic 
environment9. The colony forming units (CFU) determined by use of this growth system 
was employed to monitor viability of C. burnetii in the stored blood products. After 
separation of the components and adding C. burnetii, three of the products (whole blood, 
leukoreduced blood, and plasma) contained similar numbers of viable C. burnetii (Figure 
1A, 1B, and 1C). The number of viable organisms in RBCs was reduced compared to the 
other products (Figure 1D). This difference was statistically significant when compared to 
each of the other three blood products (p<0.022).
The number of viable C. burnetii in whole blood or in specific fractionated blood products 
did not significantly decline during the 42 days that these products were stored and 
evaluated (Figure 1). The only significant change was an apparent increase in the number of 
viable C. burnetii in plasma by day 14. There was a statistically significant difference 
between the number of CFU at day 14 compared to days 0 and 7 (p<0.03). From day 14 
through day 42, the number of viable C. burnetii in plasma did not significantly increase or 
decrease. The reason for higher numbers of bacteria in plasma at days 14–42 is not known.
To determine if the C. burnetii in the stored blood products remained infectious, aliquots 
were placed on RK13 (rabbit kidney) cells and the growth of the organisms in culture was 
monitored by quantitative PCR. As shown in Figure 2, all of the samples were infectious in 
culture and demonstrated robust growth between the two sampling points (7 and 14 days 
after inoculation of the cultures). The most robust growth was seen in the plasma samples, 
most likely due to higher numbers of bacteria introduced into the cultures.
Discussion
This study demonstrates that C. burnetii can retain significant viability and infectivity when 
kept in whole blood and blood products at 1–6°C. There was no decline in viability during 
42 days of storage. Although plasma can be stored frozen for longer periods of time, blood 
products are not typically stored past 42 days at 1–6°C. For the CPDA-1 anticoagulant used 
in this study, the recommendation is to use the whole blood or leukoreduced blood product 
within 35 days, but a 42 day shelf life can be achieved with some additional additives. 
Therefore, testing out to 42 days of storage shows that C. burnetii present in a donated blood 
product stored at 1–6°C could maintain its ability to infect a recipient for the duration of the 
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product’s shelf life. This suggests that blood product transfusion represents a possible means 
of transmitting Q fever.
For this study, C. burnetii was added to the blood products after separation, and was 
therefore present in the extracellular portion of each component. In human infections, C. 
burnetii primarily infects cells of the monocyte lineage, and can only replicate when inside a 
parasitophorous vacuole. However, there is evidence that a significant portion of C. burnetii 
is present in the extracellular compartment of human blood during infection. Early in 
infection, C. burnetii can readily be detected in human serum by PCR5, and in mouse 
experiments we have found similar numbers of C. burnetii genomes present in murine serum 
and whole blood during acute infection (unpublished observations). C. burnetii found in 
both whole blood and serum during acute infection is viable. Leukoreduction of infected 
blood may remove most or all of the intracellular C. burnetii, but the evidence suggests that 
significant numbers of organisms will remain after leukoreduction. It is difficult to test this 
idea directly because of the low availability of sufficient quantities of blood from acute Q 
fever patients. Nevertheless, the results described here demonstrate that any C. burnetii 
found in stored blood components will easily survive normal storage conditions.
C. burnetii exists in two morphological forms: the large cell variant (LCV) and the small 
cell variant (SCV). The LCV form is the replicative form and will predominate in the 
parasitophorous vacuole. The SCV form is considered to be spore-like, undergoes little or no 
replication, and has the ability to survive for extended periods under relatively harsh 
conditions. Extracellular C. burnetii will transition to the SCV after leaving the vacuole. It is 
therefore expected that the SCV form of C. burnetii will predominate in leukoreduced blood, 
plasma, or RBCs. C. burnetii in whole blood likely be a mixture of LCV and SCV and could 
convert to the SCV form during storage. Thus, the extended survival attributes of the SCV 
would be quite relevant for survival of C. burnetii in blood products.
Although the stability of C. burnetii was very similar among the different blood products, 
there were distinct differences in the growth and yield of organisms among the products. 
Immediately after spiking, the number of CFU in plasma was similar to whole blood and 
leukoreduced blood, but the number of CFU in plasma increased at day 7 and day 14. The 
possibility exists that there was some cell-free growth of C. burnetii in plasma, however it is 
more likely that whole blood contains inhibitors of C. burnetii colony formation that were 
removed in the plasma. These inhibitors may be present in RBCs, as fewer CFU were 
recovered from RBCs at all time points compared to the other products. Interestingly, the 
inhibition of growth imparted by RBCs was even observed after RBC-stored C. burnetii was 
inoculated onto RK13 cultures (Figure 2). The source of this inhibition warrants further 
study.
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Viability of C. burnetii in whole blood and blood products. Donated human blood was 
separated into leukoreduced blood, plasma, and RBCs; spiked with viable C. burnetii, and 
then stored at 1–6°C. Aliquots were taken at the indicated times and the number of colony 
forming units (CFU) in the stored blood or blood products determined by counting colony 
growth on ACCM-2 agar plates.
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C. burnetii stored in whole blood and blood products remains infectious. Donated human 
blood was separated into leukoreduced blood, plasma, and RBCs; spiked with viable C. 
burnetii, and then stored at 1–6°C. Aliquots were taken at the indicated times and used to 
inoculate cultures of RK13 rabbit kidney cells. At 7 and 14 days after inoculation an aliquot 
of the culture was analyzed by quantitative PCR targeting the C. burnetii IS1111 
transposase. A higher number of genome equivalents (GE) at day 14 indicates infection of 
the RK13 cells and growth in culture.
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